790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Bibliographic Details
Main Authors: Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Leora Horn, Frederic Triebel, Enric Carcereny, Margarita Majem, Bernard Doger, Julio Peguero, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items